A Widely Used Vaccine May Hold The Key To Slowing Aging

Scientists suggest that the shingles vaccine might offer benefits beyond preventing a painful viral illness, potentially helping to slow biological aging in older adults.

A study led by researchers at the University of Southern California found that vaccinated individuals showed reduced signs of biological aging and lower inflammation compared with those who had not received the shot.

The research, which examined more than 3,800 participants, indicates the widely used vaccine could provide additional health advantages aside from shingles prevention.

Lead author Jung Ki Kim explained that lowering background inflammation—possibly by stopping the virus from reactivating—may contribute to healthier aging. Although the exact biological processes are still unclear, reducing inflammation could support resilience and delay age-related decline.

These results add to earlier findings linking adult vaccinations, including shingles and flu shots, with decreased risks of dementia and other neurodegenerative conditions.

In the United States, the primary shingles vaccine is Shingrix. The Centers for Disease Control and Prevention recommends it for adults aged 50 and older, as well as younger adults with weakened immune systems. It is administered in two doses, usually spaced two to six months apart.

Using data from nearly 4,000 older adults, researchers evaluated several indicators of biological aging, such as immune strength, brain health, circulation, and gene activity. They concluded that chronic inflammation—often called “inflammaging”—plays a central role in aging, and reducing it may support healthier later life.